14CHADS2-Score und Schlaganfallrisiko*The adjusted stroke rate was derived from the multivariable analysis assuming no aspirin usage; these stroke rates are based on data from a cohort of hospitalised AF patients, published in 2001, with low numbers in those with a CHADS2 score of 5 and 6 to allow an accurate judgement of the risk in these patients. Given that stroke rates are declining overall, actual stroke rates in contemporary non-hospitalised cohorts may also vary from these estimates. Adapted from Gage BF et al.AF = atrial fibrillation; CHADS2 = cardiac failure, hypertension, age, diabetes, stroke (doubled).14

38ATHENA-Studie: andere EndpunkteDeath from arrhythmias was reduced by 45% (p=0.01) when patients were treated with Multaq® (dronedarone).Multaq® (dronedarone) demonstrated a lower risk of pro-arrhythmia than placebo and no excess of hospitalizations for congestive heart failure.The rate of study drug discontinuation was similar between the two study arms.JCE 2008; 19.1/Heart Rhythm 2008

39ATHENA-Studie: Adverse EventsThere was a higher frequency of reported gastro-intestinal complications in the Multaq® (dronedarone) group than in the placebo arm.Gastro-intestinal Effects (%)JCE 2008; 19.1/Heart Rhythm 200839